KR20130137912A - Composition for preventing or treating stress or depressive disorder - Google Patents

Abstract

The present invention relates to a new use of an Acer tegmentosum extract. The present invention provides a composition for preventing or treating stress or depressive disorder, containing an Acer tegmentosum extract as an active ingredient. A pharmaceutical composition or a food composition containing the Acer tegmentosum extract as an active ingredient is useful in the prevention, delay, improvement, or treatment of stress or depressive disorder.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing or treating stress or depression,

More particularly, the present invention relates to a composition for preventing or treating stress or depression comprising extracts of Prunus persica.

Modern industrial society is changing rapidly and complexly structurally and functionally. In addition, there is an enormous amount of information coming out daily, which is difficult for an individual to digest. Most of the modern people who have to adapt to new technology and new environment feel a lot of physical and psychological burden. These burdens are called stresses and can be defined as "reactions or changes that are harmful to an organism caused by external stimuli." The mental impairment that occurs in the modern complex society is not caused by a great psychological impact or stimulation, but rather by the weak but persistent and repetitive stress that occurs in daily life. These stresses are easily overlooked by the patients even if they are not recognized by the patients themselves, and the weak stimuli accumulate and lead to the depression of the individual. Depression is an emotional pathology that occurs regardless of the objective situation. All lives of the patient are covered with depressed moods, decreased in interest, become anhedonia, become depressed, depressed, and desperate. It is a disease that leads to suicidal thoughts. It shows a variety of physical symptoms such as decreased appetite, insomnia, constipation, loss of libido, and increased sensitivity to diseases caused by impaired immune function. There is no theory that fully explains the mechanism of action of antidepressants, which are antidepressants and antidepressants. However, in general, the lack of monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine in synapses of the central nervous system induces depression It is the most likely hypothesis. Thus, antidepressants all have pharmacological actions that increase the concentration of neurotransmitters in central serotonin or noradrenaline synapses. Antidepressants can be classified as tricyclic antidepressants (TCA), monoamine oxidase inhibitors (MAOI), or selective serotonin reuptake inhibitors (SSRIs) depending on the mechanisms that increase the concentration of neurotransmitters. And so on. Monoamine oxidase inhibitors, such as the relatively old phenelzine that has been developed, have not been used recently due to serious side effects of heart disease, and tricyclic antidepressants such as imipramine also have anticholinergic side effects and sedatives, Side effects remain a significant problem. Therefore, in recent years, there has been a focus on the development of a therapeutic agent for depression using a selective serotonin reuptake inhibitor (hereinafter referred to as 'SSRI') as a therapeutic agent for depression, The efficacy of fluoxetine (paroxetine), sertraline (sertraline), and sertraline (product name: zoloft) has been widely recognized as a representative drug. However, the above medicaments also exhibit side effects such as systemic fatigue, sexual dysfunction, and insomnia. Administration of a general antidepressant increases the amount of serotonin to activate the serotonin receptor and to enhance the activity of its down-stream PKA and furthermore to increase the activity of CREB, brain-derived neurotrophic factor BDNF) and its receptor, trkB, which are effective markers at the molecular level of antidepressant drugs, and these increases in BDNF or serotonin receptor activity, particularly in the hippocampus It is known that neuronal regeneration, in which damaged brain cells are restored, occurs and restores the impaired memory of depressed patients (J. of Psychosomatic Research 53, 687-697 (2002)). In addition, administration of antidepressants usually decreases the levels of cortisol, IL-2, WBC, and lymphocyte numbers, which are typical responses to immune depression in people with depression, (Ann NY Acad Sci. 917, 478-487 (2000)). These effects can also be regarded as another indication of the effectiveness of antidepressants in the treatment of depression. Recently, it has been recognized and studied the efficacy of natural medicinal herb extracts in Western countries. In relation to depression, studies using extracts of Hypericum perforatum, mainly called St. John's wort (St. John's wort) (Neuropharmacology, 1999, 21 (2), 247-257; Cochrane Database Syst Rev, 2000, (2), CD000448; Drugs Aging, 2000, 16 (3), 189-197). In a study comparing the efficacy of the extract of hyperferritum perforatum with that of imipramine, it was reported that the effect of hyperferritum perforatum in the treatment of depression was similar to that of imipramine, (BMJ, 2000, 321, 536-539) It has also been reported that the extract of hyperfercum perforatum is likely to inhibit human cytochrome P450 enzyme activity (J Pharmacol Exp Ther, 2000 , 294 (1), 88-95). Extracts of Hyperfercum perforatum contain a large number of structurally distinct compounds that act directly or indirectly on the central nervous system (CNS). That is, the extract of Hyperperfum perforatum actually contains active compounds such as hypericin, hyperforin and the like and dimeric flavones, And has been known to have an anxiolytic action. In view of its mechanism of action, hyperpericin has been shown to have antidepressant action in the presence of dimeric procyanidines contained in the extract of hyperpericum perforatum (Regensburg, Germany, V. Butterwecke et al., 45 Hyperferrin has been reported to elevate 5-HT (serotonine) levels in the hypothalamus and hippocampus of mice, and hyper- The antidepressant effect of hyperforin is presumed to be related to the serotonin system (J Pharm Pharmacol, 2001, 53 (5), 583-600; Pharmacopsychiatry, 2000, 33 (2), 60-65). However, among depressed patients, about 20% of patients are not treated with conventional antidepressants, and the adverse effects of recently developed antidepressants such as SSRI are still relatively low compared to conventional antidepressants, but still not negligible. Meanwhile, various depressive animal models have been attempted in the development of antidepressants for the treatment of depression. Initially, strong intense stimuli such as intense foot-shock, cold water immersion, 48 hours of food or water deprivation were preferred, The use of mildly repetitive stress, which can better simulate the contemporary human daily life under constant chronic stress, is preferred (Psychopharmacology, 1984, 83, 1-16). Among them, Chronic Mild Stress (CMS) model proposed by Willner et al. Is recognized as an excellent depressive animal model with reliability and validity (Neuroscience and Biobehavial Review, 1981, 5 , 231-246; TIPS, 1991, 12, 131-136). Chronic mild stressed rats show that behavioral changes induced by chronic and weak stimuli (CMS) are observed over a period of several weeks of continuous dosing and that this does not occur habitually, (Psychopharmacology, 1997, 134, 319-320). In general experiments, a variety of chronic diseases such as 24-hour light illumimation, periods of food and / or water deprivation, cage tilt, change of cage mate, (Psychopharmacology, 1997, 134, 319-320). Repeating this stress procedure, rats are a symptom equivalent to anorexia, a typical symptom of depression, and show a significant decrease in the sucrose solution intake. This reduction in intake is known to last for several weeks after withdrawing the CMS procedure if no treatment is given. Many antidepressants have been shown to be effective in restoring the reduction of sucrose intake following treatment with CMS to the original level (Psychopharmacology, 1992, 109, 433-438).

On the other hand, Acer tegmentosum Maxim. Is a plant belonging to the maple family. It is also called as a socioeconomic or mountain elm. Leaves are broad, young stem is light green, stem is very soft and broken, its shell is thick and its material is white and light. Bee is not toxic, so it has no side effects with any constitution. It is also used as a purple blood drug and a water medicine. It usually uses the water obtained from the leaves of leaves, branches, stems, and roots of the Japanese beech. It is used to treat liver diseases such as hepatitis, liver cirrhosis and liver cancer and leukemia, diabetes, nephritis and edema in the Korean peninsula. It is also used for the purpose of alcohol detoxification. In addition, it has been reported that drinking alcoholic beverages can prevent poisoning by taking the extract of the Japanese beech tree [Kim TJ: Plant Resources in Korea Vol. III, Publishing Co., Seoul, p. 50 (1996); Isolation of isoprenoid compounds from the stems of Acer tegimentosum Max, Kor. JM, Jun MR, Yang EJ, Choi SH, Park JC, Song KS. J. Pharmacogn. 38: 67-70 (2007). In addition, there are known admiral effect, amniotic function, lipolytic action, diuretic action, neurostabilizing action, and gestational action. In addition, the salidroside isolated from the stem of beech can be used for antioxidant, anti-aging, whitening effect, sleep-soothing effect, hypoglycemic effect, neuronal cell protection against oxidative stress by amyloid- , The effect on bone marrow cell cycle, and the effect on carbohydrate metabolism have been reported.

The present invention has been made under the conventional technical background, and it is an object of the present invention to provide a novel use of a perilla extract.

More specifically, it is an object of the present invention to provide a use for preventing or treating stress or depression of a Prunus persica extract.

The present inventors conducted studies to develop an extract having a preventive or therapeutic activity against stress or depression in a large number of natural products having safety compared with synthetic chemicals. As a result, it has been found that an extract obtained from Acer tegmentosum Maxim. Has an excellent preventive or therapeutic activity in an animal model of stress or depression, and thus can be usefully used for preventing or treating stress or depression.

In order to achieve the above object, the present invention provides a composition for preventing or treating stress or depression comprising an extract of Prunus mume as an active ingredient. The composition for preventing or treating stress or depression is preferably a pharmaceutical composition or a food composition.

The pharmaceutical composition or food composition containing the extract of Prunus mume extract of the present invention as an active ingredient can be usefully used for preventing, delaying, improving or treating stress or depression.

FIG. 1 is a graph showing the effect of the bee extract prepared in Preparation Example 1 of the present invention on the social interaction of an animal model of stress or depression, FIG. 2 is a graph showing the effect of the bee extract prepared in Preparation Example 2 of the present invention on stress or depression FIG. 3 is a graph showing the effect of the bee extract prepared in Preparation Example 3 of the present invention on the social interaction of an animal model of stress or depression. FIG. In FIG. 1, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of a perilla extract of Preparation Example 1, and AT400 represents a 400 mg / kg administration group of a perilla extract of Preparation Example 1. In Fig. 2, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of a perilla extract of Preparation Example 2, and AT400 represents a group administered with 400 mg / kg of a perilla extract of Preparation Example 2. In FIG. 3, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of a perilla extract of Preparation Example 3, and AT400 represents a group administered with 400 mg / kg of a perilla extract of Preparation Example 3.
FIG. 4 is a graph showing the effect of the bee extract prepared in Preparation Example 1 of the present invention on a forced swimming test of an animal model of stress or depression, FIG. 5 is a graph showing the effect of the bee extract prepared in Preparation Example 2 of the present invention on stress or depression FIG. 6 is a graph showing the effect of the bee extract prepared in Preparation Example 3 of the present invention on the forced swimming test of an animal model of stress or depression. FIG. In FIG. 4, OVX represents a control group, AT100 represents a group administered 100 mg / kg of Prunus mume extract of Preparation Example 1, and AT400 represents a 400 mg / kg administration group of Prunus mume extract of Preparation Example 1. In FIG. 5, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of Prunia extract of Preparation Example 2, and AT400 represents a group administered with 400 mg / kg of Prunia extract of Preparation Example 2. In FIG. 6, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of a perilla extract of Preparation Example 3, and AT400 represents a group administered with 400 mg / kg of a perilla extract of Preparation Example 3.

Hereinafter, terms used in the present invention will be described.

As used herein, the term "prophylactic " means any act that inhibits the symptoms of a particular disease or delays the progress of the disease upon administration of the composition of the present invention.

The term "treatment" as used herein refers to any improvement action that improves or alleviates the symptoms of a particular disease upon administration of the composition of the present invention.

The term "administering" as used herein is meant to provide any desired composition of the invention to an individual by any suitable method. The term " individual " means any animal such as a human, a monkey, a dog, a goat, a pig, or a mouse having a disease in which symptoms of a specific disease can be improved by administering the composition of the present invention.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for preventing or treating stress or depression comprising an extract of Prunus mume as an active ingredient. In the present invention, stress refers to a nonspecific biological reaction that occurs in the body against various injuries or stimuli applied to a living body, and specifically refers to stresses, rules, regulations, formal procedures, and the like caused by physical environments such as noise and closed spaces Stress, pessimistic thoughts caused by lifestyle such as stress caused by personal circumstances such as stress, economic change, unemployment, lack of sleep, excessive schedule, etc. induced by social environment or social relations , Stress caused by distorted perception such as extreme thinking, and the like. In the present invention, depression refers to a disease that causes various cognitive and psychosomatic symptoms as a main symptom with depression of desensitization and depression, resulting in deterioration of daily function. Specifically, unipolar depression (endogenous depressions) And bipolar depression, depressive neurosis, reactive depression, depressive in-case of schizoaffective psychosis, organically-based depression, And depressive symptoms in dementia. The plum extract according to the present invention can increase aggressive behavior, significantly reduce immobility, and effectively prevent or treat stress or depression in social interaction and forced swimming tests using an animal model of stress or depression.

The extract of Prunus mume, which is used as an active ingredient of the composition for the prevention or treatment of stress or depression according to the present invention, can be obtained from various organs or parts such as leaves, flowers, roots, stems, branches, Means an extract obtained from an extract, preferably from leaves, stems, branches, bark or roots. In addition, the primate extract according to the present invention can be produced by a conventional extraction method known in the art, for example, a solvent extraction method. The extraction solvent used in the preparation of the beech extract by the solvent extraction method includes water, lower alcohols having 1 to 4 carbon atoms (e.g. methanol, ethanol, propanol and butanol) or hydrated lower alcohols, May be selected from the group consisting of water, alcohols, or mixtures thereof, such as, but not limited to, acetonitrile, methylene chloride, isopropanol, . When water is used as the extraction solvent, the water is preferably hot water. For example, the extract of Prunus persica according to the present invention can be obtained by adding 5 to 20 times volume of water to bees to bees and then refluxing at 80 to 120 ° C for 2 to 8 hours, followed by filtration and lyophilization. When an alcohol is used as an extraction solvent, the alcohol is preferably a lower alcohol having 1 to 4 carbon atoms, and the lower alcohol is more preferably selected from methanol or ethanol. On the other hand, it is obvious to those skilled in the art that the extract of Prunus mume extract of the present invention can be obtained not only by the above-mentioned extraction solvent but also by using other extraction solvent, which exhibits substantially the same effect.

In addition, the Prunus persica extract of the present invention includes not only the extract obtained by the above-mentioned extraction solvent, but also the extract obtained through other conventional extraction methods, and the extract obtained through purification and fermentation processes. For example, decompression by carbon dioxide, extraction by supercritical extraction with high temperature, extraction by extraction using ultrasound, separation by ultrafiltration membrane with constant molecular weight cutoff value, various chromatography (size, charge, hydrophobic or affinity And the active fraction obtained through various purification and extraction methods, such as those extracted by fermentation products using natural or various microorganisms, are also included in the extract of the present invention.

The supercritical fluid extraction refers to supercritical fluid extraction. Generally, the supercritical fluid is extracted from the liquid and the liquid when the gas reaches the critical point at high temperature and high pressure. (J. Chromatogr. A. 1998; 479: 200-205). In addition, it has been reported that the supercritical fluid has a polarity similar to that of a nonpolar solvent. Carbon dioxide is a supercritical fluid with both liquid and gaseous nature, with the operation of supercritical fluid equipment reaching its critical pressure and temperature, resulting in increased solubility in fat-soluble solutes. When supercritical carbon dioxide passes through an extraction vessel containing a certain amount of sample, the lipophilic substance contained in the sample is extracted into supercritical carbon dioxide. When the supernatant carbon dioxide containing a small amount of cosolvent is passed through the sample remaining in the extraction vessel after extracting the lipid-soluble substance, components that were not extracted by pure supercritical carbon dioxide can be extracted. The supercritical fluid used in the supercritical extraction method of the present invention can effectively extract an active ingredient by using a mixed fluid in which a cosolvent is further mixed with supercritical carbon dioxide or carbon dioxide. These co-solvents may be used alone or in admixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether. Most of the extracted samples contain carbon dioxide. Since the carbon dioxide is volatilized into air at room temperature, the extract obtained by the above method can be used as a cosmetic composition, and the cosolvent can be removed by a reduced pressure evaporator.

In addition, the ultrasonic extraction method is an extraction method using energy generated by ultrasonic vibration. Ultrasonic waves can destroy an insoluble solvent contained in a sample in a water-soluble solvent. Due to the high local temperature, Since the kinetic energy of the reactant particles is increased, sufficient energy required for the reaction is obtained. By inducing the high pressure by the shock effect of the ultrasonic energy, the mixing effect of the substance contained in the sample and the solvent is enhanced, thereby increasing the extraction efficiency. As the extraction solvent which can be used for the ultrasonic extraction method, one or a mixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether can be used. The extracted sample is recovered by vacuum filtration, and the filtrate is recovered, and the extract is removed by a vacuum evaporator and freeze-dried to obtain an extract.

The Prunus persica extract according to the present invention includes an extract obtained through fermentation, and the fermented extract of Prunus persica can be prepared as follows. After finely crushing the extraction site (leaves, flowers, roots, stems, branches, husks, seeds, etc.) of the beech to about 100 to 500 mesh, 1 to 50 g / L of a conventional microorganism culture solution is added, The microorganism is added in an amount of 10,000 to 100,000 cfu / L. The culture temperature is 30 to 37 ° C. The pH is 5 to 7 and aerobically or usually anaerobic conditions are incubated for about 5 to 10 days. Which can be obtained through aging and filtration.

In addition, the extract of Prunus persica according to the present invention contains Flavonoid and Glycoside as an active substance. However, depending on the extraction method, there may be slight differences in the kind and content of the specific components of the active ingredient of the perilla extract. Flavonoids are collectively referred to as a group of substances having a C ₆ -C ₃ -C ₆ carbon skeleton structure in which two phenyl groups are bonded through a C ₃ chain, which is a yellow pigment widely distributed in foods. Beolnamu extract according to the present invention preferably quercitrin (Quercitrin), campaign roll-3 ramno seed (kaempferol-3-rhamnoside), high-Transferrin (Hyperin), paroxetine gwereu 3-O - Samburu rainy seed (Quercetin- 3- O -sambubioside), citrine advance (Myricitrin), 6- hydroxy-gwereu paroxetine -3- O - galactose (6-hydroxyquercetin-3- O -galactose ), pre-dihydro-paroxetine (dihydromyricetin), (+) - catechins [(+) - catechin], Gallo catechin (gallocatechin) and (+) - catechin --3- O - (3,4- dihydroxy benzoyl) [(+) - catechin- 3- O - (3, (Tung, NH, Ding, Y., Kim, SK, Bae, K., Kim, K., , YH, 2008. Total peroxyl radical scavenging capacity of the chemical components from the stems of Acer tegmentosum Maxim. Journal of Agriculture and Food Chemistry 56, 10510-10514.). A glycoside is a molecule in which anomeric carbon existing in a sugar group binds to a non sugar group to form a glycosidic bond. In this case, the glycoside may be referred to as a glycone or an aglycone aglycone. The plum extract according to the present invention comprises a glucoside in which the aglycone is a phenylethyl group or a hydrophenylethyl group, preferably 4-hydroxy-phenylethyl- O - ? - D-glucopyranoside (4- hydroxy-phenylethyl- O - β -D- glucopyranoside), 6'- O - galloyl raised draw seed (6'- O -galloylsalidroside), 3'- O - salicylate galloyl draw seed (3'- O -galloylsalidroside) and phenyl ethyl - O - (β -D- xylene in pyrazol nosil - (1 → 2) - β -D- glucopyranoside) [Phenylethyl- O - (β- D-xylopyranosyl- (1 → 2) -β (Tung, NH, Ding, Y., Kim, SK, Bae, K.), and more preferably at least one glycoside selected from the group consisting of , Kim, YH, 2008. Total peroxyl radical scavenging capacity of the chemical components from the stems of Acer tegmentosum Maxim. Journal of Agriculture and Food Chemistry 56, 10510-10514.).

The composition for prevention or treatment of stress or depression comprising the extract of Prunus persica Asiatica as an active ingredient of the present invention may be applied to a pharmaceutical composition, a food composition (in particular, a functional food composition), a cosmetic composition (in particular, a functional cosmetic composition) Additives, and the like.

In the pharmaceutical composition of the present invention, the content of Prunus persica extract is 0.1 to 99% by weight, preferably 0.5 to 50% by weight, more preferably 1 to 30% by weight based on the total weight of the composition, but is not limited thereto. The pharmaceutical composition of the present invention may further comprise additives such as pharmaceutically acceptable carriers, excipients or diluents in addition to the extract of Prunus persica. Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In addition, the composition for preventing or treating depression of the present invention may further contain at least one known active ingredient having a preventive or therapeutic effect on stress or depression, in addition to the extract of Prunus persica.

The pharmaceutical composition of the present invention can be formulated into a formulation for oral administration or parenteral administration by a conventional method, and can be formulated into a pharmaceutical composition such as a filler, an extender, a binder, a wetting agent, a disintegrant, Diluents or excipients. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, Sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like. Further, it can be suitably formulated according to each disease or ingredient, using appropriate methods in the art or by the method disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA.

The pharmaceutical composition of the present invention may be administered orally or parenterally to a mammal including a human according to a desired method. Examples of the parenteral administration method include external dermal application, intraperitoneal injection, intramuscular injection, subcutaneous injection, intravenous injection, Intravenous injection or intra-thoracic injection. The dosage of the pharmaceutical composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity. A typical daily dose of the pharmaceutical composition of the present invention is 0.1 to 1000 mg / kg, preferably 1 to 500 mg / kg, based on the extract of Prunum alba, an effective ingredient, .

The food composition of the present invention may be in the form of a pill, a powder, a granule, an infusion, a tablet, a capsule, or a liquid preparation. Examples of the food include meat, sausage, bread, chocolate, candy, snack, Other noodles, gums, dairy products including ice cream, various soups, drinks, tea, functional water, drinks, alcoholic beverages and vitamin complexes.

The content of the beech extract in the food composition of the present invention is 0.01 to 50 wt%, preferably 0.1 to 25 wt%, more preferably 0.5 to 10 wt%, based on the total weight of the composition, but is not limited thereto. The food composition of the present invention may contain various flavoring agents or natural carbohydrates as an additional ingredient in addition to the cinnamon extract. In addition, the food composition of the present invention can be used as a food composition containing various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. In addition, the food composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The above-mentioned natural carbohydrates are sugar alcohols such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol and erythritol. Natural flavors such as tau Martin and stevia extract, and synthetic flavors such as saccharin and aspartame may be used as the flavor.

In the cosmetic composition of the present invention, the content of the extract is from 0.01 to 30% by weight, preferably from 0.01 to 20% by weight, more preferably from 0.1 to 10% by weight, based on the total weight of the composition. The cosmetic composition of the present invention may contain components commonly used in cosmetic compositions in addition to the cinnamon extract, and includes conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers.

The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used in the form of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder. When the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide Can be used. When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan. When the formulation of the cosmetic composition of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used. When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, Propellants such as carbon, propane / butane or dimethyl ether. When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

The cosmetic composition of the present invention may be used alone or in combination, or may be used in combination with other cosmetic compositions other than the present invention. The cosmetic composition according to the present invention may be used according to a conventional method of use, and may be used in a number of times depending on the skin condition or taste of the user. When the cosmetic composition of the present invention is a soap, a surfactant-containing cleansing formulation or a surfactant-free cleansing formulation, it may be applied to the skin and then wiped off, washed or rinsed with water. The surfactant-containing cleansing formulation may be a cleansing foam, a cleansing water, a cleansing towel and a cleansing pack. The surfactant-free cleansing formulation may be a cleansing cream, , Cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.

The feed additive of the present invention may contain, for example, 0.1 to 20% by weight of Prunus mume extract, 0.001 to 0.01% by weight of lipase, 1 to 20% by weight of calcium tertiary phosphate, 0.01 to 0.1% by weight of vitamin E, To 10% by weight of lactic acid bacteria, 0.1 to 10% by weight of lactic acid bacteria, 0.01 to 10% by weight of a culture medium of Bacillus and 20 to 90% by weight of glucose, but is not particularly limited thereto. , As feed additives of the present invention. The effective amount means an amount capable of preventing or treating depression, or preventing or treating colitis, by steadily ingesting poultry, livestock, and the like. Also, an amount that does not cause an adverse effect beyond the profit due to the addition is preferable. The feed additive may additionally contain a carrier such as poultry and livestock. In the present invention, the feed additive may be added as it is or a known carrier, stabilizer and the like may be added. Various nutrients such as vitamins, amino acids and minerals, antioxidants, antibiotics, antibacterial agents and other additives may be added And the shape thereof may be a suitable state such as powder, granule, pellet, suspension and the like. When the feed additive of the present invention is supplied, it can be supplied to poultry, livestock and the like singly or mixed with feed.

Hereinafter, the present invention will be described more specifically with reference to the following examples. However, the following examples are intended to clearly illustrate the present invention and do not limit the scope of protection of the present invention.

One. Prick  Preparation of extract

Production Example 1

Distilled water corresponding to about 10 times as much as the weight of the shade twigs and the twig twigs after shredding was placed in an extraction container equipped with a cooler and reflux-extracted at about 100 ° C for about 4 hours. The extract was filtered with gauze, concentrated at a bath temperature of about 80 ° C, and then lyophilized to prepare a powdery bee extract.

Production Example 2

About 10 times as much methanol as the weight of shrubs and leaves after shredding was added to an extraction vessel equipped with a condenser and refluxed at room temperature for about 5 hours. The extract was filtered with Wattmann filter paper (Whatman # 4), concentrated under reduced pressure at about 40 ° C, and then lyophilized to prepare a powdered beech extract.

Production Example 3

Approximately 10 times 70% aqueous ethanol solution was added to the extraction container equipped with a cooler after refining and refluxed at room temperature for about 5 hours. The extract was filtered with Wattmann filter paper (Whatman # 4), concentrated under reduced pressure at about 40 ° C, and then lyophilized to prepare a powdered beech extract.

2. Prick  Extract Antistress  Efficacy or antidepressant effect test

(1) an animal model of stress or depression

Sprague Dawley female rats weighing about 220 ~ 250g (Samtaco, Gyeonggi-do, Korea) were used as experimental animals. During the adaptation to the breeding environment, water and feed were allowed to freely eat, the temperature of the breeding room was maintained at 22 ± 2 ° C, the humidity was maintained at 55 to 60%, and the light-dark cycle was adjusted to 12 hours.

The rats were anesthetized by intraperitoneal injection of pentobarbital sodium at a dose of 50 mg / kg and then incised 1 cm along the median center line of the spinal cord. Then, the ovaries were exposed and the blood vessels were ligated with sutures and the ovaries were excised.

After ovariectomy, they were restored for a week and then subjected to restraint stress. Specifically, the stressed rats were transferred to the laboratory from the animal room at 9:30 am every morning, and stress was applied for 2 hours from 10 am using a disposable scalloped plastic bag.

(2) Social interaction test

 Immediately before the stress-induced rats were given stress for 2 hours each morning, the Prunus persica extracts prepared in Preparations 1 to 3 were orally administered at a dose of 100 mg / kg or 400 mg / kg on the basis of Prunus persica extract. At this time, the extract of Prunus persicae was administered to rats in the form dissolved in physiological saline. In the control group, only physiological saline was orally administered. In all the experiments, 6 dogs were used. After 2 weeks of stress, the experimental group was allowed to interact 1: 1 with the rats in the new cage, and then they were observed for active behavior such as glooming, rearing, sniffing Sniffing, and Licking, and then assessed social interaction.

FIG. 1 is a graph showing the effect of the bee extract prepared in Preparation Example 1 of the present invention on the social interaction of an animal model of stress or depression, FIG. 2 is a graph showing the effect of the bee extract prepared in Preparation Example 2 of the present invention on stress or depression FIG. 3 is a graph showing the effect of the bee extract prepared in Preparation Example 3 of the present invention on the social interaction of an animal model of stress or depression. FIG. In FIG. 1, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of a perilla extract of Preparation Example 1, and AT400 represents a 400 mg / kg administration group of a perilla extract of Preparation Example 1. In Fig. 2, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of a perilla extract of Preparation Example 2, and AT400 represents a group administered with 400 mg / kg of a perilla extract of Preparation Example 2. In FIG. 3, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of a perilla extract of Preparation Example 3, and AT400 represents a group administered with 400 mg / kg of a perilla extract of Preparation Example 3. As shown in FIGS. 1 to 3, the action of Puerariae Radix extract-treated group was more active than that of the control group, and the increase of active action was dependent on the dose of Puerariae Radix extract.

(3) Forced Swimming test

The Forced Swimming test is known as a basic experiment to detect the antidepressant effect in the development of antidepressant drugs. After 2 weeks of stress, the rats were allowed to stand at a temperature of about 22 ° C in a cylindrical water tank of 50 cm in height and 30 cm in diameter to a height not reaching the floor, and allowed to stand for 15 minutes. For the first few minutes, the rats show great resistance to escape from the situation, but as the time passes, the time to show more and more floating positions increases. After 15 minutes of forced swimming, rats were orally administered to the rats at a dose of 100 mg / kg or 400 mg / kg on the basis of the extract of Prunus persica Extract prepared in Preparation Examples 1 to 3, After 23 hours, oral administration was once again administered. At this time, the extract of Prunus persicae was administered to rats in the form dissolved in physiological saline. In the control group, only physiological saline was orally administered. In all the experiments, 6 dogs were used. When 24 hours had elapsed from the administration of primate extract, the mice were forced to swim again for 5 minutes in the same environment and the immobility time was measured. Immobility is a state in which the mouse is exposed to the surface of the body, including the face, while keeping the balance of the body, with no movement of the limbs.

FIG. 4 is a graph showing the effect of the bee extract prepared in Preparation Example 1 of the present invention on a forced swimming test of an animal model of stress or depression, FIG. 5 is a graph showing the effect of the bee extract prepared in Preparation Example 2 of the present invention on stress or depression FIG. 6 is a graph showing the effect of the bee extract prepared in Preparation Example 3 of the present invention on the forced swimming test of an animal model of stress or depression. FIG. In FIG. 4, OVX represents a control group, AT100 represents a group administered 100 mg / kg of Prunus mume extract of Preparation Example 1, and AT400 represents a 400 mg / kg administration group of Prunus mume extract of Preparation Example 1. In FIG. 5, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of Prunia extract of Preparation Example 2, and AT400 represents a group administered with 400 mg / kg of Prunia extract of Preparation Example 2. In FIG. 6, OVX represents a control group, AT100 represents a group administered with 100 mg / kg of a perilla extract of Preparation Example 3, and AT400 represents a group administered with 400 mg / kg of a perilla extract of Preparation Example 3. As shown in FIG. 4 to FIG. 6, the floating state of plum extract-treated group was significantly decreased compared to the control group (p <0.05).

3. Prick  Preparation of Pharmaceutical Compositions Containing Extracts

<3-1> Manufacture of powder

2 g of the extract of Preparation Example 1

Lactose 1 g

The above components were mixed and packed in airtight bags to prepare powders.

<3-2> Preparation of tablets

100 mg of the extract of Preparation Example 1

Corn starch 100 mg

100 mg of milk

Magnesium stearate 2 mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

&Lt; 3-3 > Preparation of capsules

100 mg of the extract of Preparation Example 1

Corn starch 100 mg

100 mg of milk

2 mg of magnesium stearate

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

&Lt; 3-4 >

1 g of the extract of Preparation Example 1

Lactose 1.5 g

Glycerin 1 g

0.5 g of xylitol

After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.

<3-5> Preparation of granules

150 mg of the extract of Preparation Example 1

Soybean extract 50 mg

200 mg of glucose

600 mg of starch

After mixing the above components, 100 mg of 30% ethanol was added and the mixture was dried at 60 캜 to form granules, which were then filled in a capsule.

<3-6> Preparation of Injection

100 mg of the extract of Preparation Example 1

Sodium metabisulphite 3.0 mg

Methyl paraben 0.8 mg

0.1 mg of propylparaben

Sterile sterilized water for injection

After mixing the above ingredients, 2 ml of the mixture was filled in an ampoule and sterilized to prepare an injection.

4. Prick  Preparation of Food Composition Containing Extracts

<4-1> Production of flour food

0.5-5.0 parts by weight of the extract of Preparation Example 1 of the present invention was added to wheat flour and the mixture was used to prepare bread, cake, cookies, crackers and noodles.

<4-2> Manufacture of soups and gravies

0.1 to 5.0 parts by weight of the extract of Preparation Example 1 of the present invention was added to soups and gravies to prepare meat products for health promotion, soups of noodles and juices.

<4-3> Preparation of ground beef

10 parts by weight of the extract of Preparation Example 1 of the present invention was added to ground beef to prepare ground beef for health promotion.

<4-4> Manufacture of dairy products

5 to 10 parts by weight of the extract of Preparation Example 1 of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

<4-5> Manufacturing of Sunshine

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.

Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.

The extract of Preparation Example 1 of the present invention was concentrated under reduced pressure in a vacuum concentrator, dried by spraying, and dried with a hot-air drier, and the dried material was pulverized to a size of 60 mesh with a pulverizer to obtain a dry powder.

The grains, seeds, and extracts of Preparation Example 1 prepared above were blended in the following proportions.

(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

The extract (3 parts by weight) of Preparation Example 1,

(0.5 part by weight),

(0.5 parts by weight)

<4-6> Manufacture of health drinks

(5 g) of the extract of Preparation Example 1 of the present invention was homogeneously mixed with a raw material such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5% Sterilized, and packaged in glass bottles, plastic bottles, and other small containers.

<4-7> Manufacture of vegetable juice

5 g of the extract of Preparation Example 1 of the present invention was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice.

<4-8> Preparation of fruit juice

1 g of the extract of Preparation Example 1 of the present invention was added to 1,000 ml of apple or grape juice to prepare fruit juice.

5. Prick  Containing an extract Cosmetics  Preparation of composition

<5-1> Production of flexible lotion

The number of softening times was prepared according to the usual method as shown in Table 1 below.

ingredient Content (unit:% by weight) The Prunus mume extract of Preparation Example 1
glycerin
1,3-butylene glycol
PEG 1500
Allantoin
DL-Panthenol
Lee D. TEE-2NA
Benzophenone-9
Sodium hyaruronate
ethanol
Octidodeces-16
Polysorbate 20
Preservative, fragrance, pigment
Distilled water 3.0
5.0
3.0
1.0
0.1
0.3
0.02
0.04
5.0
10.0
0.2
0.1
a very small amount
Balance Sum 100

<5-2> Production of convergent lotion

The convergent lotion was prepared according to a conventional method as shown in Table 2 below.

ingredient Content (unit:% by weight) The Prunus mume extract of Preparation Example 1
glycerin
1,3-butylene glycol
Allantoin
DL-Panthenol
Lee D. TEE-2NA
Benzophenone-9
Sodium hyaruronate
ethanol
Polysorbate 20
Location of Hazel extract
Citric acid
Preservative, fragrance, pigment
Distilled water 1.5
2.0
2.0
0.2
0.2
0.02
0.04
3.0
15.0
0.3
2.0
a very small amount
a very small amount
Balance Sum 100

<5-3> Production of nutrition lotion

Nutritional lotion was prepared according to the usual method as shown in Table 3 below.

ingredient Content (unit:% by weight) The Prunus mume extract of Preparation Example 1
Stearyl alcohol
lanolin
Polysorbate 60
Sorbitan stearate
Hardened vegetable oil
Mineral oil
Squalane
Trioctanoin
Dimethicone
Tocopheryl acetate
Carboxyvinyl polymer
glycerin
1,3-butylene glycol
Sodium hyaruronate
Triethanolamine
Preservative, fragrance, pigment
Distilled water 1.5
1.5
1.5
1.3
0.5
1.0
5.0
3.0
2.0
0.8
0.5
0.12
5.0
3.0
5.0
0.12
a very small amount
Balance Sum 100

<5-4> Preparation of nutritional cream

Nutritive creams were prepared according to the usual methods as shown in Table 4 below.

ingredient Content (unit:% by weight) The Prunus mume extract of Preparation Example 1
Pro-type glycerin monostearate
Cetearyl alcohol
Stearic acid
Wax
Polysorbate 60
Sorbitan stearate
Hardened vegetable oil
Squalane
Mineral oil
Trioctanoin
Dimethicone
Sodium magnesium silicate
glycerin
Betaine
Triethanolamine
Sodium hyaruronate
Preservative, fragrance, pigment
Distilled water 3.0
2.0
2.2
1.5
1.0
1.5
0.6
1.0
3.0
5.0
5.0
1.0
0.1
5.0
3.0
1.0
4.0
a very small amount
Balance Sum 100

<5-5> Manufacture of massage cream

Massage creams were prepared according to the usual method as shown in Table 5 below.

ingredient Content (unit:% by weight) The Prunus mume extract of Preparation Example 1
Chin type glycerin monosuccinic acid
Stearyl alcohol
Stearic acid
Polysorbate 60
Sorbitan stearate
Isostearyl isoserate
Squalane
Mineral oil
Dimethicone
Hydroxyethyl cellulose
glycerin
Triethanolamine
Preservative, fragrance, pigment
Distilled water 3.0
1.5
1.5
1.0
1.5
0.6
5.0
5.0
35.0
0.5
0.12
6.0
0.7
a very small amount
Balance Sum 100

<5-6> Production of essence

The essence was prepared according to a conventional method as shown in Table 6 below.

ingredient Content (unit:% by weight) The Prunus mume extract of Preparation Example 1
glycerin
Betaine
PIZZY 1500
Allantoin
DL-Panthenol
Lee D. T.-2Na
Benzophenone-9
Hydroxyethyl cellulose
Sodium hyaruronate
Carboxyvinyl polymer
Triethanolamine
Octyldodecanol
Octyldodec-16
ethanol
Preservative, fragrance, pigment
Distilled water 5.0
10.0
5.0
2.0
0.1
0.3
0.02
0.04
0.1
8.0
0.2
0.18
0.3
0.4
6.0
a very small amount
Balance Sum 100

<5-7> Manufacture of pack

The pack was prepared according to a conventional method as shown in Table 7 below.

ingredient Content (unit:% by weight) The Prunus mume extract of Preparation Example 1
Polyvinyl alcohol
Cellulose sword
glycerin
PIZZY 1500
Cyclostristin
DL - Panthenol
Allantoin
Monoammonium glycyrrhizin acid
Nicotinamide
ethanol
FYGEN 40 Hardened castor oil
Fragrance, coloring, preservative
Distilled water 3.0
15.0
0.15
3.0
2.0
0.15
0.4
0.1
0.3
0.5
6.0
0.3
a very small amount
Balance Sum 100

6. Prick  Preparation of Feed Additives Containing Extracts

<6-1> Feed Additive 1

0.1 to 20 parts by weight of a perilla plant extract of Preparation Example 1, 0.001 to 0.01 part by weight of lipase, 1 to 20 parts by weight of calcium phosphate, 0.01 to 0.1 part by weight of vitamin E, 1 to 10 parts by weight of enzyme powder, 0.1 to 10 parts by weight of a lactic acid bacterium, 0.01 to 10% by weight of a culture medium of Bacillus and 20 to 90 parts by weight of glucose were mixed to prepare a feed additive.

<6-2> Feed Additive 2

A feed additive was prepared by blending 24 parts by weight of a Prunus mume extract of Preparation Example 1, 24 parts by weight of a perennial herb extract, 1 part by weight of a lactic acid bacterium, 10 parts by weight of yeast, 1 part by weight of colostrum, 20 parts by weight of glucose and 20 parts by weight of alfalfa powder.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. In addition, many modifications may be made to adapt a particular situation and material to the teachings of the invention without departing from the essential scope thereof. Accordingly, the scope of protection of the present invention should be construed as including all embodiments falling within the scope of the following claims.

Claims (10)

A composition for preventing or treating stress or depression comprising an extract of Prunus mume as an active ingredient.
The composition for preventing or treating stress or depression according to claim 1, wherein the extract is extracted with water, alcohol or a mixture thereof.
The composition for preventing or treating stress or depression according to claim 2, wherein the water is hot water.
The composition for preventing or treating stress or depression according to claim 1, wherein the honeycomb is leaf, branch, stem, bark or root.
[Claim 3] The method according to claim 1, wherein the Prunia extract is obtained by adding 5 to 20 times volume of water to bees to a beech tree, refluxing the extract at 80 to 120 DEG C for 2 to 8 hours, filtering and lyophilizing the extract. &Lt; / RTI &gt;
[Claim 2] The method according to claim 1, wherein the Prunia extract comprises Flavonoid and Glycoside as an active substance,
Wherein the glycoside is an aglycone having a phenylethyl group or a hydrophenylethyl group.
7. The method of claim 6 wherein the flavonoid is quercitrin (Quercitrin), campaign roll-3 ramno seed (kaempferol-3-rhamnoside), high-Transferrin (Hyperin), paroxetine gwereu 3-O - Samburu rainy seed (Quercetin-3 - O -sambubioside), citrine advance (Myricitrin), 6- hydroxy-gwereu paroxetine -3- O - galactose (6-hydroxyquercetin-3- O -galactose ), pre-dihydro-paroxetine (dihydromyricetin), (+) - catechin [(+) - catechin], Gallo catechin (gallocatechin) and (+) - catechin --3- O - (3,4- dihydroxy benzoyl) [(+) - catechin-3- O - (3,4 -dihydroxybenzoyl)]. &lt; / RTI &gt;
7. The method of claim 6 wherein the glycoside seed 4-hydroxy-phenyl-ethyl-O-β -D- glucopyranoside (4-hydroxy-phenylethyl- O - β -D-glucopyranoside), 6'- O - galloyl salicylate draw seed (6'- O -galloylsalidroside), 3'- O - galloyl raised draw seed (3'- O -galloylsalidroside) ethyl and phenyl - O - a (β -D- xylene pyrazol nosil - (1 → 2 ) - ? - D-glucopyranoside) [Phenylethyl- O- (? -D-xylopyranosyl- (1? 2) -? - D-glucopyranoside)]. Or &lt; / RTI &gt;
9. The composition for preventing or treating stress or depression according to any one of claims 1 to 8, wherein the composition is a pharmaceutical composition.
9. A composition for preventing or treating stress or depression according to any one of claims 1 to 8, wherein the composition is a food composition.

Images